Literature DB >> 11535214

A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation.

S A Sanders1, C A Graham, J L Bass, J Bancroft.   

Abstract

The purpose of the study was to explore predictors of discontinuation of oral contraceptives (OC) including pre-OC use characteristics and adverse physical, emotional, and sexual effects of OCs. Women aged 18+ years in committed, sexually active relationships were assessed before starting OC and reassessed at 3, 6, and 12 months or shortly after discontinuation. Assessment included pre-OC use attitudes and expectations about the pill; self-reported side effects and perimenstrual symptoms including premenstrual syndrome (PMS); physical and emotional well-being; and sexual interest, enjoyment, and frequency of sexual activity. Seventy-nine women completed the study, 38% continued OCs, 47% discontinued, and 14% switched to another OC. Emotional side effects, worsening of PMS, decreased frequency of sexual thoughts, and decreased psychosexual arousability correctly categorized 87% of cases by using logistic regression. Emotional and sexual side effects were the best predictors of discontinuation/switching, yet such OC effects have been largely ignored in the research literature.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535214     DOI: 10.1016/s0010-7824(01)00218-9

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  54 in total

1.  Acute exercise improves physical sexual arousal in women taking antidepressants.

Authors:  Tierney A Lorenz; Cindy M Meston
Journal:  Ann Behav Med       Date:  2012-06

Review 2.  Noncontraceptive health benefits of oral contraceptives.

Authors:  Andrew M Kaunitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 3.  Studying the use of oral contraception: a review of measurement approaches.

Authors:  Kelli Stidham Hall; Katharine O'Connell White; Nancy Reame; Carolyn Westhoff
Journal:  J Womens Health (Larchmt)       Date:  2010-10-30       Impact factor: 2.681

4.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

5.  Dual method use at last sexual encounter: a nationally representative, episode-level analysis of US men and women.

Authors:  Jenny A Higgins; Nicole K Smith; Stephanie A Sanders; Vanessa Schick; Debby Herbenick; Michael Reece; Brian Dodge; J Dennis Fortenberry
Journal:  Contraception       Date:  2014-06-12       Impact factor: 3.375

6.  Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States.

Authors:  Katherine M Keyes; Keely Cheslack-Postava; Carolyn Westhoff; Christine M Heim; Michelle Haloossim; Kate Walsh; Karestan Koenen
Journal:  Am J Epidemiol       Date:  2013-09-15       Impact factor: 4.897

7.  Effect of an oral contraceptive with chlormadinone acetate on depressive mood : analysis of data from four observational studies.

Authors:  Johannes C Huber; Marie-Luise S Heskamp; Georg A K Schramm
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

8.  The influence of hormonal contraception on mood and sexual interest among adolescents.

Authors:  Mary A Ott; Marcia L Shew; Susan Ofner; Wanzhu Tu; J Dennis Fortenberry
Journal:  Arch Sex Behav       Date:  2008-02-21

9.  Female social and sexual interest across the menstrual cycle: the roles of pain, sleep and hormones.

Authors:  Chrisalbeth J Guillermo; Heidi A Manlove; Peter B Gray; David T Zava; Chandler R Marrs
Journal:  BMC Womens Health       Date:  2010-05-27       Impact factor: 2.809

10.  Mood and sexual side effects of hormonal contraception: physicians' and residents' knowledge, attitudes, and practices.

Authors:  Ellen Wiebe; Janusz Kaczorowski; Jacqueline Mackay
Journal:  Can Fam Physician       Date:  2012-11       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.